Plant Name: Artocarpus communis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.412E-07 | 2.626E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 2.412E-07 | 2.626E-03 | ACHE, BCHE |
| BP | GO:0050896; response to stimulus | GO:0050727; regulation of inflammatory response | 7.393E-07 | 3.018E-03 | CYP19A1, ESR1, NFKB1, PTGS2, RELA |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.447E-06 | 4.500E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:2000630; positive regulation of miRNA metabolic process | 2.410E-06 | 5.832E-03 | NFKB1, RELA |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.874E-06 | 6.259E-03 | ACHE, BCHE, ESR1, ESR2, NFKB1, PTGS2, RELA |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 4.095E-06 | 7.344E-03 | ACHE, BCHE, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 4.835E-06 | 7.344E-03 | ESR1, ESR2, NFKB1, RELA |
| BP | GO:0032501; multicellular organismal process | GO:0045075; regulation of interleukin-12 biosynthetic process | 5.059E-06 | 7.344E-03 | NFKB1, RELA |
| CC | GO:0032991; macromolecular complex | GO:0033256; I-kappaB/NF-kappaB complex | 5.059E-06 | 7.344E-03 | NFKB1, RELA |
| BP | GO:0009987; cellular process | GO:0071316; cellular response to nicotine | 6.743E-06 | 9.177E-03 | NFKB1, RELA |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.189E-08 | 2.296E-06 | ESR1; RELA; NFKB1; ESR2 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.496E-06 | 1.979E-04 | PTGS2; RELA; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.013E-06 | 2.053E-04 | PTGS2; RELA; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.690E-05 | 2.267E-04 | CTSK; RELA; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.889E-05 | 2.267E-04 | PTGS2; RELA; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.141E-05 | 2.053E-04 | PTGS2; RELA; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.886E-05 | 3.109E-04 | CTSK; RELA; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.260E-05 | 2.934E-04 | CTSK; RELA; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.451E-05 | 2.521E-04 | ADORA3; RELA; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.721E-04 | 1.781E-03 | PTGS2; CYP19A1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.613E-04 | 1.781E-03 | RELA; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.539E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.295E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.539E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.745E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 4.602E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.397E-04 | 2.296E-03 | PTGS2; NFKB1; RELA |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.036E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.802E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 4.462E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.602E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.802E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 5.336E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.609E-04 | 2.296E-03 | RELA; NFKB1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 5.336E-04 | 1.816E-03 | RELA; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.107E-03 | 2.484E-03 | RELA; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 9.597E-04 | 2.468E-03 | RELA; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.064E-03 | 2.484E-03 | ESR1; ESR2 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 6.124E-04 | 1.837E-03 | RELA; NFKB1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.085E-03 | 2.484E-03 | RELA; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.042E-04 | 2.296E-03 | RELA; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.151E-03 | 2.484E-03 | RELA; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.173E-03 | 2.484E-03 | RELA; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.173E-03 | 2.484E-03 | RELA; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.287E-03 | 2.648E-03 | RELA; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.506E-03 | 3.012E-03 | RELA; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.557E-03 | 3.029E-03 | RELA; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.292E-03 | 4.126E-03 | RELA; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.993E-03 | 3.679E-03 | RELA; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.449E-03 | 4.301E-03 | RELA; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.907E-03 | 3.614E-03 | RELA; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.271E-03 | 5.608E-03 | RELA; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.382E-03 | 5.657E-03 | RELA; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 4.331E-03 | 6.496E-03 | RELA; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.725E-03 | 5.830E-03 | RELA; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.457E-03 | 5.657E-03 | RELA; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.206E-03 | 6.443E-03 | RELA; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.457E-03 | 6.549E-03 | RELA; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 3.647E-03 | 5.830E-03 | RELA; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.435E-03 | 7.827E-03 | RELA; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 6.811E-03 | 9.616E-03 | RELA; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.967E-03 | 9.647E-03 | RELA; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.192E-02 | 1.589E-02 | RELA; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.142E-03 | 1.242E-02 | PTGS2; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.026E-02 | 4.831E-02 | PTGS2 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.009E-02 | 3.732E-02 | PTGS2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.766E-02 | 3.556E-02 | PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.058E-02 | 3.732E-02 | PTGS2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.863E-02 | 3.617E-02 | CYP19A1 |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | 2.326E-02 | 3.045E-02 | ESR1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteopenia | M85.8 | CTSK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CTSK; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; ESR1; ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Bone disease | M00-M99 | CTSK |
| C00-D49: Neoplasms | Bone metastases | C79.51 | CTSK |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ostereoporosis | M80-M81 | CTSK |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CTSK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CTSK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |